نتایج جستجو برای: آنتیبادی مونوکلونال trastuzumab

تعداد نتایج: 9324  

Trastuzumab is a specific monoclonal antibody used for therapeutic of the human epidermal growth factor receptor 2 (HER-2) -positive metastatic breast cancer. But, resistance to trastuzumab is a major obstacle in clinical efficiency.  During the past years, several studies have been done to find the mechanisms contributing to trastuzumab resistance. Previous studies have highlighted that bone m...

Journal: :international journal of hematology-oncology and stem cell research 0
mehrdad payandeh department of hematology and medical oncology, kermanshah university of medical sciences, kermanshah, iran masoud sadeghi students research committee, kermanshah university of medical sciences, kermanshah, iran medical biology research center, kermanshah university of medical sciences, kermanshah, iran edris sadeghi students research committee, kermanshah university of medical sciences, kermanshah, iran medical biology research center, kermanshah university of medical sciences, kermanshah, iran alireza janbakhsh department of infectious diseases and tropical medicine, kermanshah university of medical sciences, kermanshah, iran

background : in developed or developing countries, the most common cancer in women is breast cancer with a pick in 40–50 years in asia. herein, we compared the association between ihc with fish in her2-positive breast cancer patients and affection of trastuzumab on disease free survival and overall survival (os). subjects and methods: immunohistochemical (ihc) analysis of hormone receptors and ...

ژورنال: :فیض 0
منصوره مومن هروی mansoure momen heravi department of infectious diseases, kashan university of medical sciences, kashan, iranکاشان، کیلومتر 5 بلوار قطب راوندی، بیمارستان شهید بهشتی، گروه عفونی علیرضا شریف ali reza sharif سید غلامعباس موسوی sayed gholam abbas moosavi

سابقه و هدف: کارکنان بهداشتی، درمانی همواره در معرض خطر ابتلا به هپاتیت  bمیباشند. این مطالعه با هدف تعیین سطح سرمی آنتـــــیبادی anti hbs در پرسنل درمانی واکسینه شده علیه هپاتیت b و تأثیر فاکتورهای مؤثر برآن انجام گرفت.مواد و روشها: مطالعه به روش توصیفی روی 128 نفر از پرسنل درمانی بیمارستان شهید بهشتی کاشان که همگی به طور کامل علیه هپاتیت b واکسینه شده بودند، در سال 1381، انجام گرفت. از افراد ...

Amir Jalilian, Behrooz Alirezapour, Fatemeh Bolourinovin Sedigheh Moradkhani

Breast cancer radioimmunoscintigraphy targeting HER2/neu expression is a growing fieldof work in nuclear medicine research. In this study, trastuzumab was successively labeledwith [67Ga] GaCl3 after conjugation with DOTA-NHS-ester.The conjugates were purified by molecular filtration, the average number ofDOTA conjugated per mAb was calculated and total concentration was determined byspectrophot...

ژورنال: :مجله علمی دانشگاه علوم پزشکی قزوین 0
مینو یغمایی m .yaghmaei آدرس مکاتبه : زاهدان، صندوق پستی 185- 98165 ، تلفن 2415736- 0541 مهدی محمدی m mohammadi سید مهدی پهلوانی s.m .pahlavani

¯ چکیده ‍ زمینه : هایپرامزیس گراویداروم یکی از عوارض جدی حاملگی است که می تواند سبب اختلال سلامت مادر و جنین شود. هدف : مطالعه به منظورتعیین ارتباط آنتی بادی ضد هلیکو باکتر پیلوری با بیماری هایپرامزیس گراویداروم انجام شد. مواد و روشها : در این مطالعه مورد- شاهدی که در سال 1381 در بیمارستان قدس زاهدان انجام شد، 40 زن مبتلا به هایپرامزیس گراویداروم از نظر وجود و تیتر آنتیبادی ضد هلیکوباکتر پیلوری...

ژورنال: کومش 2020

Introduction: ELISA is a sensitive, specific, reproducible and fast method to quantify the biological activity of antibodies. Trastuzumab is a humanized monoclonal antibody against HER2 receptors which prevents the initiation of downstream signaling pathway. Trastuzumab can be used as a positive control in the ELISA experiments for anti-HER2 antibodies. Additionaly, insufficient washing and blo...

Journal: :iranian journal of pharmaceutical research 0
behrooz alirezapour agricultural, medical and industrial research school (amirs), nuclear science and technology research institute, rajaeeshahr, karaj, iran, p.o.box: 31485-498. amir jalilian nuclear science research school, nuclear science and technology research institute, tehran, 11365-3486, iran. fatemeh bolourinovin agricultural, medical and industrial research school (amirs), nuclear science and technology research institute, rajaeeshahr, karaj, iran, p.o.box: 31485-498. sedigheh moradkhani agricultural, medical and industrial research school (amirs), nuclear science and technology research institute, rajaeeshahr, karaj, iran, p.o.box: 31485-498.

breast cancer radioimmunoscintigraphy targeting her2/neu expression is a growing fieldof work in nuclear medicine research. in this study, trastuzumab was successively labeledwith [67ga] gacl3 after conjugation with dota-nhs-ester.the conjugates were purified by molecular filtration, the average number ofdota conjugated per mab was calculated and total concentration was determined byspectrophot...

2017
Zéna Wimana Geraldine Gebhart Thomas Guiot Bruno Vanderlinden Denis Larsimont Gilles Doumont Gaetan Van Simaeys Serge Goldman Patrick Flamen Ghanem Ghanem

Trastuzumab remains an important drug in the management of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer (BC). Several studies reported resistance mechanisms to trastuzumab, including impaired HER2-accessibility caused by mucin 4 (MUC4). Previously, we demonstrated an increase of Zirconium-89-radiolabeled-trastuzumab (89Zr-Trastuzumab) accumulation when MUC4-overe...

Journal: :Molecular cancer therapeutics 2011
Maurizio Scaltriti Violeta Serra Emmanuel Normant Marta Guzman Olga Rodriguez Alice R Lim Kelly L Slocum Kip A West Varenka Rodriguez Ludmila Prudkin José Jimenez Claudia Aura José Baselga

Hsp90 facilitates the maturation and stability of numerous oncoproteins, including HER2. The aim of this study was to assess the antitumor activity of the Hsp90 inhibitor IPI-504 in trastuzumab-resistant, HER2-overexpressing breast cancer cells. Therapy with trastuzumab, IPI-504, and the combination of trastuzumab and IPI-504 was evaluated in trastuzumab-sensitive and trastuzumab-resistant cell...

Journal: :International journal of oncology 2008
Takashi Sumikawa Yasushi Shigeoka Tadashi Igishi Hisashi Suyama Akira Yamasaki Kiyoshi Hashimoto Shingo Matsumoto Kenichi Takeda Yasuto Ueda Eiji Shimizu

The combination of trastuzumab with paclitaxel (PTX) is an important option for the treatment of HER2-positive breast cancer. Dexamethasone (Dex) premedication is routinely used in the treatment with PTX. The interactions among Dex, PTX and trastuzumab were evaluated in BT-474 cells. Dex interfered with trastuzumab-induced cell growth inhibition without clear effects on PTX-induced cytotoxicity...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید